Aerie Pharmaceuticals Inc Ret. on assets
What is the Ret. on assets of Aerie Pharmaceuticals Inc?
The Ret. on assets of Aerie Pharmaceuticals Inc is -9.21%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Health Care sector on NASDAQ compared to Aerie Pharmaceuticals Inc
What does Aerie Pharmaceuticals Inc do?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Companies with ret. on assets similar to Aerie Pharmaceuticals Inc
- ModivCare has Ret. on assets of -9.22%
- NexGen Ltd has Ret. on assets of -9.22%
- QuinStreet Inc has Ret. on assets of -9.22%
- Winfull has Ret. on assets of -9.22%
- Sri Adhikari Brothers Television Network has Ret. on assets of -9.21%
- QMC Quantum Minerals Corp has Ret. on assets of -9.21%
- Aerie Pharmaceuticals Inc has Ret. on assets of -9.21%
- Tree House Education & Accessories has Ret. on assets of -9.20%
- Star Equity has Ret. on assets of -9.20%
- eSun has Ret. on assets of -9.18%
- Xinji Shaxi Co., Ltd has Ret. on assets of -9.18%
- BCM Resources has Ret. on assets of -9.18%
- Arbor Metals has Ret. on assets of -9.18%